Coding Glossary
ICD-9-CM (International Classification of Diseases, 9th Edition)
ICD-9-CM codes represent the patient’s medical condition or reason for treatment (diagnosis code). These codes are used by hospitals and physicians, and are recognized by all insurers.
NDC (National Drug Code)
NDCs are codes that identify FDA-approved drugs. The NDC identifies the manufacturer, product, and package size. NDCs are used primarily by retail pharmacies.
HCPCS (Healthcare Common Procedure Coding System)
HCPCS codes are assigned by CMS (Center for Medicare and Medicaid Services) and are used by Medicare and most private payers to describe products administered in the physician office or hospital setting.
CPT-4 (Current Procedural Terminology)
CPT-4 Codes are used by physicians and hospitals to designate the procedures performed.
Revenue Codes
Revenue Codes are used by hospitals to classify services by category, and typically are required by payers when billing infusions in the hospital setting.
Indication & Usage
Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:
- anemia
- thrombocytopenia
- bone disease
- hepatomegaly or splenomegaly
Important Safety Information
Approximately 15% of patients have developed IgG antibodies, and these patients have a higher risk of hypersensitivity reaction. Therefore periodic monitoring is suggested; caution should be exercised in patients with antibodies or prior symptoms of hypersensitivity. Symptoms suggestive of hypersensitivity occurred in 6.6% of patients, and include anaphylactoid reaction, pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis and hypotension.
Reactions related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported adverse events include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Adverse events associated with the route of administration include discomfort, pruritus, burning, swelling or sterile abscess at the site at the site of injection.
To report suspected adverse reactions, contact Genzyme at 800-745-4447, option 2 or FDA at 800-FDA-1088 or http://www.fda.gov/Safety/MedWatch
Please see Full Prescribing Information (PDF).